ARCALIS, Inc, is a CDMO to manufacture mRNA therapeutic drugs for vaccines targeting cancer and rare diseases along with infectious disease, providing our customers with seamless services from mRNA design to large-scale manufacturing. Our commercial production of self-amplifying mRNA (saRNA)-LNP, Kostaive, for COVID-19 vaccine started in 2024 at our drug substance facility. In this presentation, the strategy to develop safe and effective mRNA-based therapeutics will be presented to introduce our strategies regarding nucleotide sequence optimization, minimization of undesirable dsRNA, mRNA-LNP formulation and our commercial manufacturing of saRNA.

Speaker:

Hamid Trimech
Business Development Manager, Arcalis
TIDES Talks in Poster and Exhibit Halls
(Grand Ballroom and Harbor Ballroom)
Wednesday, 21 May 2025 3:50pm – 4:00pm